Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Inclusion Criteria: * Parent or legal guardian is willing and able to provide written informed consent; when applicable potential participant is willing and able to provide written assent * Age 8-14 years (inclusive) at entry * Received birth dose of BCG vaccine * Has a negative nucleic acid test result for M.tb at screening and no other evidence of current active TB disease at screening * M.tb sensitization status (positive or negative) determined based on IGRA testing at screening * HIV status determined * For participants living with HIV: has been receiving antiretroviral therapy for at least six months prior to study entry, has a CD4+ cell count of at least 200 cells/mm\^3 at screening, has had a suppressed HIV viral load for at least three months prior to entry * Has normal or grade 1 results for all of the following at screening: Hemoglobin, White blood cell count, Platelet count, Creatinine, ALT, AST, Total bilirubin * Has a normal temperature and no signs or symptoms of acute illness * For participants assigned female sex at birth or who could otherwise become pregnant: not pregnant * For participants assigned female sex at birth or who could otherwise breastfeed: not breastfeeding * Expected to be available for 48 weeks of study participation * Not expected to participate in any other study of an investigational agent during the 48 weeks of study participation Exclusion Criteria: * Known significant exposure to TB or receipt of tuberculin skin test in the six mont…